Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CHRS |
---|---|---|
09:32 ET | 158908 | 1.0891 |
09:33 ET | 72403 | 1.0597 |
09:35 ET | 72354 | 1.055 |
09:37 ET | 111249 | 1.015 |
09:39 ET | 99556 | 1.02 |
09:42 ET | 41073 | 1.02 |
09:44 ET | 25697 | 1.03 |
09:46 ET | 83093 | 1.025 |
09:48 ET | 14812 | 1.03 |
09:50 ET | 25523 | 1.0388 |
09:51 ET | 12063 | 1.035 |
09:53 ET | 44955 | 1.0488 |
09:55 ET | 16105 | 1.03 |
09:57 ET | 16344 | 1.03 |
10:00 ET | 2972 | 1.035 |
10:02 ET | 6105 | 1.045 |
10:04 ET | 18471 | 1.045 |
10:06 ET | 3581 | 1.0419 |
10:08 ET | 4582 | 1.045 |
10:09 ET | 7415 | 1.0483 |
10:11 ET | 77992 | 1.055 |
10:13 ET | 5800 | 1.055 |
10:15 ET | 10625 | 1.065 |
10:18 ET | 65414 | 1.075 |
10:20 ET | 5765 | 1.07 |
10:22 ET | 23540 | 1.0701 |
10:24 ET | 15200 | 1.085 |
10:26 ET | 6227 | 1.075 |
10:27 ET | 10973 | 1.0798 |
10:29 ET | 20081 | 1.07 |
10:31 ET | 16962 | 1.075 |
10:33 ET | 52025 | 1.065 |
10:36 ET | 500 | 1.06 |
10:38 ET | 35562 | 1.06 |
10:40 ET | 18198 | 1.0633 |
10:42 ET | 1108 | 1.06 |
10:44 ET | 11155 | 1.06 |
10:45 ET | 17818 | 1.06 |
10:47 ET | 12121 | 1.06 |
10:49 ET | 5374 | 1.07 |
10:51 ET | 103282 | 1.1 |
10:54 ET | 28870 | 1.1055 |
10:56 ET | 37429 | 1.1173 |
10:58 ET | 38472 | 1.1101 |
11:00 ET | 17893 | 1.105 |
11:02 ET | 2812 | 1.1083 |
11:03 ET | 7311 | 1.1199 |
11:05 ET | 13428 | 1.1099 |
11:07 ET | 41676 | 1.1 |
11:09 ET | 8876 | 1.0988 |
11:12 ET | 15805 | 1.1088 |
11:14 ET | 16300 | 1.11 |
11:16 ET | 23111 | 1.125 |
11:18 ET | 21210 | 1.125 |
11:20 ET | 37106 | 1.14 |
11:21 ET | 11730 | 1.13 |
11:23 ET | 33652 | 1.1412 |
11:25 ET | 21173 | 1.145 |
11:27 ET | 43598 | 1.14 |
11:30 ET | 3980 | 1.14 |
11:32 ET | 5620 | 1.1301 |
11:34 ET | 41632 | 1.14 |
11:36 ET | 25168 | 1.14 |
11:38 ET | 6627 | 1.1299 |
11:39 ET | 11046 | 1.11 |
11:41 ET | 2700 | 1.11 |
11:43 ET | 62884 | 1.1 |
11:45 ET | 39296 | 1.105 |
11:48 ET | 1777 | 1.1 |
11:50 ET | 16006 | 1.1 |
11:52 ET | 3801 | 1.1 |
11:54 ET | 4287 | 1.105 |
11:56 ET | 2142 | 1.1 |
11:57 ET | 80846 | 1.105 |
11:59 ET | 70003 | 1.13 |
12:01 ET | 5047 | 1.13 |
12:03 ET | 20351 | 1.125 |
12:06 ET | 39772 | 1.145 |
12:08 ET | 27634 | 1.15 |
12:10 ET | 12141 | 1.145 |
12:12 ET | 63323 | 1.1599 |
12:14 ET | 41418 | 1.15 |
12:15 ET | 11315 | 1.15 |
12:17 ET | 7083 | 1.15 |
12:19 ET | 14545 | 1.15 |
12:21 ET | 9757 | 1.15 |
12:24 ET | 4675 | 1.15 |
12:26 ET | 3143 | 1.15 |
12:28 ET | 12100 | 1.145 |
12:30 ET | 27300 | 1.15 |
12:32 ET | 33443 | 1.15 |
12:33 ET | 400 | 1.15 |
12:35 ET | 1742 | 1.145 |
12:37 ET | 4033 | 1.1412 |
12:39 ET | 24297 | 1.1527 |
12:42 ET | 14900 | 1.155 |
12:44 ET | 4929 | 1.1588 |
12:46 ET | 69136 | 1.1625 |
12:48 ET | 250 | 1.165 |
12:50 ET | 5371 | 1.165 |
12:51 ET | 22536 | 1.15 |
12:53 ET | 13220 | 1.15 |
12:55 ET | 6485 | 1.15 |
12:57 ET | 35000 | 1.145 |
01:00 ET | 26910 | 1.145 |
01:02 ET | 16000 | 1.145 |
01:04 ET | 5350 | 1.1419 |
01:06 ET | 6845 | 1.145 |
01:08 ET | 23205 | 1.1491 |
01:09 ET | 900 | 1.15 |
01:11 ET | 7038 | 1.155 |
01:13 ET | 26334 | 1.145 |
01:15 ET | 420 | 1.145 |
01:18 ET | 15000 | 1.15 |
01:20 ET | 57175 | 1.15 |
01:22 ET | 10596 | 1.155 |
01:24 ET | 17636 | 1.15 |
01:26 ET | 14501 | 1.15 |
01:27 ET | 792 | 1.155 |
01:29 ET | 11333 | 1.15 |
01:31 ET | 12806 | 1.15 |
01:33 ET | 23768 | 1.154 |
01:36 ET | 6667 | 1.15 |
01:38 ET | 9023 | 1.15 |
01:40 ET | 128924 | 1.141 |
01:42 ET | 11999 | 1.1485 |
01:44 ET | 6400 | 1.15 |
01:45 ET | 1806 | 1.145 |
01:47 ET | 55032 | 1.15 |
01:49 ET | 2834 | 1.14 |
01:51 ET | 3400 | 1.1477 |
01:54 ET | 70972 | 1.135 |
01:56 ET | 90363 | 1.15 |
01:58 ET | 15683 | 1.1512 |
02:00 ET | 41621 | 1.15 |
02:02 ET | 3686 | 1.145 |
02:03 ET | 750 | 1.145 |
02:05 ET | 10082 | 1.1423 |
02:07 ET | 34518 | 1.1307 |
02:09 ET | 3738 | 1.14 |
02:12 ET | 12325 | 1.135 |
02:14 ET | 454 | 1.135 |
02:16 ET | 38000 | 1.105 |
02:18 ET | 26233 | 1.11 |
02:20 ET | 10909 | 1.11 |
02:23 ET | 9964 | 1.12 |
02:25 ET | 26310 | 1.129 |
02:27 ET | 3300 | 1.12 |
02:30 ET | 3100 | 1.1254 |
02:32 ET | 500 | 1.12 |
02:34 ET | 276 | 1.13 |
02:36 ET | 400 | 1.125 |
02:38 ET | 541 | 1.13 |
02:39 ET | 3400 | 1.125 |
02:41 ET | 2300 | 1.125 |
02:43 ET | 5646 | 1.125 |
02:45 ET | 2582 | 1.125 |
02:48 ET | 3634 | 1.1247 |
02:50 ET | 84089 | 1.115 |
02:52 ET | 24761 | 1.1 |
02:54 ET | 29875 | 1.105 |
02:56 ET | 32973 | 1.1 |
02:57 ET | 96800 | 1.09 |
02:59 ET | 93807 | 1.085 |
03:01 ET | 3440 | 1.08 |
03:03 ET | 11380 | 1.085 |
03:06 ET | 10460 | 1.0805 |
03:08 ET | 62233 | 1.0888 |
03:10 ET | 68921 | 1.07 |
03:12 ET | 3827 | 1.07 |
03:14 ET | 4499 | 1.07 |
03:15 ET | 4232 | 1.0788 |
03:17 ET | 8265 | 1.07 |
03:19 ET | 5369 | 1.07 |
03:21 ET | 8934 | 1.07 |
03:24 ET | 14815 | 1.07 |
03:26 ET | 29452 | 1.07 |
03:28 ET | 6690 | 1.07 |
03:30 ET | 42819 | 1.085 |
03:32 ET | 27955 | 1.08 |
03:33 ET | 36298 | 1.0799 |
03:35 ET | 14623 | 1.0701 |
03:37 ET | 21942 | 1.075 |
03:39 ET | 6100 | 1.07 |
03:42 ET | 11204 | 1.075 |
03:44 ET | 19740 | 1.085 |
03:46 ET | 20784 | 1.08 |
03:48 ET | 33664 | 1.08 |
03:50 ET | 14054 | 1.085 |
03:51 ET | 17572 | 1.085 |
03:53 ET | 8205 | 1.085 |
03:55 ET | 67416 | 1.11 |
03:57 ET | 15010 | 1.11 |
04:00 ET | 207982 | 1.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Coherus BioSciences Inc | 126.7M | -12.3x | --- |
Voyager Therapeutics Inc | 296.1M | 9.2x | --- |
Ginkgo Bioworks Holdings Inc | 378.8M | -0.5x | --- |
Amarin Corporation PLC | 215.9M | -5.5x | --- |
Revance Therapeutics Inc | 402.8M | -2.0x | --- |
Vanda Pharmaceuticals Inc | 288.0M | -17.5x | -37.98% |
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $126.7M |
---|---|
Revenue (TTM) | $304.3M |
Shares Outstanding | 115.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-0.09 |
Book Value | $-1.72 |
P/E Ratio | -12.3x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | 26.1x |
Operating Margin | 8.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.